Immune Checkpoint Blockade

Jarushka Naidoo; David B. Page; Jedd D. Wolchok

doi:10.1016/j.hoc.2014.02.002

Immune Checkpoint Blockade

Jarushka Naidoo
, David B. Page
, Jedd D. Wolchok

Research output: Contribution to journal › Review article › peer-review

77 Scopus citations

Abstract

Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.

Original language	English
Pages (from-to)	585-600
Number of pages	16
Journal	Hematology/Oncology Clinics of North America
Volume	28
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2014.02.002
State	Published - Jun 2014

Keywords

Anti-CTLA4
Anti-PD-1
Anti-PD-L1
Checkpoint inhibitor
Immunotherapy
Ipilimumab
Nivolumab
Tremelimumab

Access to Document

10.1016/j.hoc.2014.02.002

Cite this

@article{653619be1a2c49c285a319d22157a0d0,

title = "Immune Checkpoint Blockade",

abstract = "Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.",

keywords = "Anti-CTLA4, Anti-PD-1, Anti-PD-L1, Checkpoint inhibitor, Immunotherapy, Ipilimumab, Nivolumab, Tremelimumab",

author = "Jarushka Naidoo and Page, \{David B.\} and Wolchok, \{Jedd D.\}",

year = "2014",

month = jun,

doi = "10.1016/j.hoc.2014.02.002",

language = "English",

volume = "28",

pages = "585--600",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Immune Checkpoint Blockade

AU - Naidoo, Jarushka

AU - Page, David B.

AU - Wolchok, Jedd D.

PY - 2014/6

Y1 - 2014/6

N2 - Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.

AB - Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma.

KW - Anti-CTLA4

KW - Anti-PD-1

KW - Anti-PD-L1

KW - Checkpoint inhibitor

KW - Immunotherapy

KW - Ipilimumab

KW - Nivolumab

KW - Tremelimumab

UR - https://www.scopus.com/pages/publications/84901413409

U2 - 10.1016/j.hoc.2014.02.002

DO - 10.1016/j.hoc.2014.02.002

M3 - Review article

C2 - 24880949

AN - SCOPUS:84901413409

SN - 0889-8588

VL - 28

SP - 585

EP - 600

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Immune Checkpoint Blockade

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this